Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4836282 | 0.86 | MEN1 (0.42) | NR1H2SMN1; SMN2HSD17B10ALDH1A1MEN1 | |
| SCHEMBL19964293 | 0.86 | CA1 (0.46) | NR1H2SMN1; SMN2NR1H3CA1CA2 | |
| SCHEMBL22709903 | 0.86 | NR1H2 (0.39) | NR1H2SMN1; SMN2HSD17B10NR1H3 | |
| SCHEMBL4836292 | 0.84 | HSD17B10 (0.39) | NR1H2SMN1; SMN2HSD17B10NR1H3ALDH1A1 | |
| SCHEMBL2157015 | 0.82 | NR1H2 (0.48) | NR1H2SMN1; SMN2HSD17B10NR1H3MEN1 | |
| SCHEMBL2157059 | 0.82 | NR1H2 (0.48) | NR1H2SMN1; SMN2HSD17B10NR1H3MEN1 | |
| SCHEMBL2157021 | 0.82 | NR1H2 (0.48) | NR1H2SMN1; SMN2HSD17B10NR1H3MEN1 | |
| SCHEMBL26796816 | 0.81 | HSD17B10 (0.46) | SMN1; SMN2HSD17B10ALDH1A1MEN1KMT2A | |
| SCHEMBL28019383 | 0.81 | NR1H2 (0.40) | NR1H2SMN1; SMN2HSD17B10NR1H3 | |
| SCHEMBL31757719 | 0.81 | BRD4 (0.41) | NR1H2SMN1; SMN2HSD17B10NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-10689377-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10633381-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144444-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | NR1H2 1539/4885SMN1; SMN2 4385/4885HSD17B10 3889/4885 |
| US-10633381-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | NR1H2 1539/4885SMN1; SMN2 4385/4885HSD17B10 3889/4885 |
| US-10689377-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | NR1H2 1539/4885SMN1; SMN2 4385/4885HSD17B10 3889/4885 |
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | NR1H2 1539/4885SMN1; SMN2 4385/4885HSD17B10 3889/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | NR1H2 1539/4885SMN1; SMN2 4385/4885HSD17B10 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.